{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096165","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.943259+00:00","generated_at":"2026-05-31T09:44:22.182529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kezar Life Sciences reports Q2 2024 net loss $21.5M; stops KZR-261 Phase 1, revises PORTOLA data to H1 2025","bullets":["Net loss $21.5M ($0.30 per share) vs $24.3M ($0.34) in Q2 2023; cash $164.2M (down from $201.4M Dec 2023).","Enrollment completed in PORTOLA Phase 2a for autoimmune hepatitis; topline data expected first half 2025 (revised from prior guidance).","Enrollment stopped in KZR-261 Phase 1 for refractory solid tumors; no objective responses observed, resources redirected to zetomipzomib.","PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.","R&D expenses down $4.7M to $16.3M vs $21.0M; restructuring charge $1.5M related to office space impairment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096165","json":"https://secwatch.observer/filing/0000950170-24-096165.json","markdown":"https://secwatch.observer/filing/0000950170-24-096165.md","text":"https://secwatch.observer/filing/0000950170-24-096165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024096165/0000950170-24-096165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024096165/kzr-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:22.182529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}